EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation

Yuxuan Wang, Jiajun Xie, Sergiu Pasca, Maria Popoli, Janine Ptak, Lisa Dobbyn, Natalie Silliman, Suman Paul iD, Richard J Jones, Mark J Levis, Samuel D Curtis iD, Christopher Douville und 11 weitere

Proceedings of the National Academy of Sciences · 21.04.2026 · 123 (16)

DOI: 10.1073/pnas.2537987123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.04.2026. Verfasst von Yuxuan Wang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the NIH (FNIH), HHS | NIH (NIH), Virginia and D.K. Ludwig Fund for Cancer Research (D.K. Ludwig Fund).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic cell transplantation is the only curative option for many patients with acute myeloid leukemia (AML). In the current study, we designed and implemented a personalized assay, called v96, incorporating up to 96 mutations in 30 AML patients undergoing transplantation. The assay was performed on DNA derived from cells isolated from the bone marrow as well as in cell-free plasma. All 30 (100%) of patients harbored molecular evidence of residual leukemia during remission that was detectable by the v96 assay, while only 6 (20%) had evidence of disease as assessed by conventional clinical assays. Furthermore, cell-free DNA from plasma proved to be more sensitive than DNA from cells of the bone marrow for identifying residual leukemia. The median number of mutants was 352-fold higher in plasma taken prior to transplantation for patients who relapsed compared to those who did not relapse. At 2 mo posttransplantation, 27 of the 30 patients still harbored detectable leukemia as assessed by the v96 assay. Twenty-two of these patients had a subsequent decrease in leukemic burden assessed by the v96 assay. In the majority of them (20 of 22 patients), the decrease occurred only after immunosuppression was discontinued, supporting a graft-versus-leukemia effect. These results document the feasibility of using a relatively large panel of carefully chosen mutations and a highly specific assay as noninvasive markers of therapeutic response in AML patients, minimizing the need for multiple bone marrow biopsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALeukemia, Myeloid, AcuteAdultAgedHumansMiddle AgedBone Marrow TransplantationMolecular Diagnostic TechniquesMutationNeoplasm, ResidualTransplantation, Homologous

Stichwörter der Autor:innen

acute myeloid leukemiactDNAmeasurable residual disease

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
  • The Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
  • Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
  • Division of Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
  • The HHMI, Baltimore, MD 21287.
  • Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287.

ORCID-Profile: Suman Paul, Samuel D Curtis, Bert Vogelstein, Lukasz P Gondek

Förderung

  • Foundation for the NIH (FNIH)
  • HHS | NIH (NIH)
  • Virginia and D.K. Ludwig Fund for Cancer Research (D.K. Ludwig Fund)
  • Commonwealth Fund (CF)
  • V Foundation for Cancer Research (VFCR)
  • Burroughs Wellcome Fund (BWF)

Zitieren

APA

Wang, Y., Xie, J., Pasca, S., Popoli, M., Ptak, J., Dobbyn, L., Silliman, N., Paul, S., Jones, R. J., Levis, M. J., Curtis, S. D., Douville, C., Shams, C., Guo, M. Z., Mo, S., Gocke, C. D., Malek, S. N., Bollard, C. M., Bettegowda, C., …, & Gondek, L. P. (2026). A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation. Proceedings of the National Academy of Sciences, 123(16). https://doi.org/10.1073/pnas.2537987123

Vancouver

Wang Y, Xie J, Pasca S, Popoli M, Ptak J, Dobbyn L, et al. A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation. Proceedings of the National Academy of Sciences. 2026;123(16). doi:10.1073/pnas.2537987123

BibTeX
@article{Wang2026,
  author = {Wang, Yuxuan and Xie, Jiajun and Pasca, Sergiu and Popoli, Maria and Ptak, Janine and Dobbyn, Lisa and Silliman, Natalie and Paul, Suman and Jones, Richard J and Levis, Mark J and Curtis, Samuel D and Douville, Christopher and Shams, Cynthia and Guo, Matthew Z and Mo, Shirley and Gocke, Christopher D and Malek, Sami N and Bollard, Catherine M and Bettegowda, Chetan and Kinzler, Kenneth W and Vogelstein, Bert and Papadopoulos, Nickolas and Gondek, Lukasz P},
  title = {A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {16},
  doi = {10.1073/pnas.2537987123}
}
Kostenlos starten →